D
Amneal Pharmaceuticals, Inc.
AMRX
$7.42
-$0.395-5.06%
D
Sell
3/3/2025Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D- from D+ on 3/3/2025 due to a substantial decline in the efficiency index, total return index and solvency index. Net income declined 19,823.72% from -$156 to -$31.08M, debt to equity increased from -27.3 to -22.9, and total capital declined 2.39% from $2.61B to $2.55B.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D- from D+ on 3/3/2025 due to a substantial decline in the efficiency index, total return index and solvency index. Net income declined 19,823.72% from -$156 to -$31.08M, debt to equity increased from -27.3 to -22.9, and total capital declined 2.39% from $2.61B to $2.55B.
D
Sell
12/12/2024Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D+ from C- on 12/12/2024 due to a decline in the total return index.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D+ from C- on 12/12/2024 due to a decline in the total return index.
C
Hold
11/13/2024Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C- from D- on 11/13/2024 due to a substantial increase in the efficiency index, total return index and volatility index.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C- from D- on 11/13/2024 due to a substantial increase in the efficiency index, total return index and volatility index.
D
Sell
5/14/2024Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D- from E+ on 5/14/2024 due to a significant increase in the growth index, valuation index and volatility index. Earnings per share increased from -$0.4048 to -$0.3, total revenue increased 6.84% from $616.98M to $659.19M, and EBIT increased 4.66% from $81.39M to $85.18M.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D- from E+ on 5/14/2024 due to a significant increase in the growth index, valuation index and volatility index. Earnings per share increased from -$0.4048 to -$0.3, total revenue increased 6.84% from $616.98M to $659.19M, and EBIT increased 4.66% from $81.39M to $85.18M.
E
Sell
3/25/2024Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to E+ from C- on 3/25/2024 due to a significant decline in the growth index, efficiency index and valuation index. Net income declined 1,118.89% from $9.68M to -$98.65M, earnings per share declined from $0.06 to -$0.4048, and total capital declined 6.15% from $3B to $2.81B.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to E+ from C- on 3/25/2024 due to a significant decline in the growth index, efficiency index and valuation index. Net income declined 1,118.89% from $9.68M to -$98.65M, earnings per share declined from $0.06 to -$0.4048, and total capital declined 6.15% from $3B to $2.81B.
C
Hold
11/14/2023Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C- from D- on 11/14/2023 due to a substantial increase in the efficiency index, valuation index and total return index.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C- from D- on 11/14/2023 due to a substantial increase in the efficiency index, valuation index and total return index.
D
Sell
8/9/2023Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D- from D on 8/9/2023 due to a substantial decline in the efficiency index and solvency index.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D- from D on 8/9/2023 due to a substantial decline in the efficiency index and solvency index.
D
Sell
6/17/2022Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D from D+ on 6/17/2022 due to a decline in the total return index.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D from D+ on 6/17/2022 due to a decline in the total return index.
D
Sell
5/6/2022Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D+ from D on 5/6/2022 due to a significant increase in the growth index and total return index. Operating cash flow increased 90.23% from $63.26M to $120.34M, and earnings per share increased from -$0.0427 to -$0.0144.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D+ from D on 5/6/2022 due to a significant increase in the growth index and total return index. Operating cash flow increased 90.23% from $63.26M to $120.34M, and earnings per share increased from -$0.0427 to -$0.0144.
D
Sell
4/18/2022Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D from D+ on 4/18/2022 due to a decline in the volatility index and valuation index.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D from D+ on 4/18/2022 due to a decline in the volatility index and valuation index.
D
Sell
3/28/2022Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D+ from D on 3/28/2022 due to a noticeable increase in the volatility index.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D+ from D on 3/28/2022 due to a noticeable increase in the volatility index.
D
Sell
11/18/2021Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D from D+ on 11/18/2021 due to a decline in the total return index and volatility index.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D from D+ on 11/18/2021 due to a decline in the total return index and volatility index.
D
Sell
11/10/2021Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D+ from C- on 11/10/2021 due to a significant decline in the growth index and volatility index. Earnings per share declined from $0.0975 to -$0.03, EBIT declined 20.61% from $72.11M to $57.25M, and total revenue declined 1.21% from $535.08M to $528.59M.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D+ from C- on 11/10/2021 due to a significant decline in the growth index and volatility index. Earnings per share declined from $0.0975 to -$0.03, EBIT declined 20.61% from $72.11M to $57.25M, and total revenue declined 1.21% from $535.08M to $528.59M.
C
Hold
10/1/2021Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C- from D+ on 10/1/2021 due to an increase in the total return index and volatility index.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C- from D+ on 10/1/2021 due to an increase in the total return index and volatility index.
D
Sell
9/16/2021Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D+ from C- on 9/16/2021 due to a decline in the volatility index and valuation index.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D+ from C- on 9/16/2021 due to a decline in the volatility index and valuation index.
C
Hold
8/27/2021Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C- from D+ on 8/27/2021 due to an increase in the total return index and volatility index.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C- from D+ on 8/27/2021 due to an increase in the total return index and volatility index.
D
Sell
8/12/2021Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D+ from D on 8/12/2021 due to a substantial increase in the efficiency index and valuation index. Net income increased 116.7% from $6.71M to $14.53M, and total capital increased 0.64% from $3.33B to $3.35B.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D+ from D on 8/12/2021 due to a substantial increase in the efficiency index and valuation index. Net income increased 116.7% from $6.71M to $14.53M, and total capital increased 0.64% from $3.33B to $3.35B.
D
Sell
5/11/2021Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D from C on 5/11/2021 due to a significant decline in the valuation index, efficiency index and growth index. Total revenue declined 3.32% from $510.03M to $493.11M, and total capital declined 0.62% from $3.35B to $3.33B.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D from C on 5/11/2021 due to a significant decline in the valuation index, efficiency index and growth index. Total revenue declined 3.32% from $510.03M to $493.11M, and total capital declined 0.62% from $3.35B to $3.33B.
C
Hold
3/8/2021Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C from C- on 3/8/2021 due to a large increase in the growth index, valuation index and efficiency index. Operating cash flow increased 136.64% from $44.78M to $105.96M, net income increased 66.16% from -$8.98M to -$3.04M, and earnings per share increased from -$0.0608 to -$0.0206.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C from C- on 3/8/2021 due to a large increase in the growth index, valuation index and efficiency index. Operating cash flow increased 136.64% from $44.78M to $105.96M, net income increased 66.16% from -$8.98M to -$3.04M, and earnings per share increased from -$0.0608 to -$0.0206.
C
Hold
2/8/2021Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C- from D+ on 2/8/2021 due to an increase in the volatility index and growth index.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to C- from D+ on 2/8/2021 due to an increase in the volatility index and growth index.
D
Sell
11/9/2020Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D+ from D on 11/9/2020 due to a significant increase in the valuation index, efficiency index and growth index. EBIT increased 142.3% from $14.93M to $36.18M, earnings per share increased from -$0.0814 to -$0.0608, and net income increased 25.18% from -$12M to -$8.98M.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D+ from D on 11/9/2020 due to a significant increase in the valuation index, efficiency index and growth index. EBIT increased 142.3% from $14.93M to $36.18M, earnings per share increased from -$0.0814 to -$0.0608, and net income increased 25.18% from -$12M to -$8.98M.
D
Sell
7/16/2020Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D from D- on 7/16/2020 due to an increase in the total return index.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D from D- on 7/16/2020 due to an increase in the total return index.
D
Sell
7/1/2020Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D- from D on 7/1/2020 due to a decline in the volatility index.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D- from D on 7/1/2020 due to a decline in the volatility index.
D
Sell
6/11/2020Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D from D- on 6/11/2020 due to an increase in the volatility index and total return index.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to D from D- on 6/11/2020 due to an increase in the volatility index and total return index.
D
Sell
5/26/2020Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D- from D on 5/26/2020 due to a significant decline in the efficiency index, total return index and growth index.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D- from D on 5/26/2020 due to a significant decline in the efficiency index, total return index and growth index.
D
Sell
3/6/2019Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D from D+ on 3/6/2019 due to a substantial decline in the valuation index, total return index and growth index. Earnings per share declined from $0.05 to -$0.0689, and EBIT declined 22.58% from $93.33M to $72.26M.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D from D+ on 3/6/2019 due to a substantial decline in the valuation index, total return index and growth index. Earnings per share declined from $0.05 to -$0.0689, and EBIT declined 22.58% from $93.33M to $72.26M.
D
Sell
1/9/2019Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D+ from C- on 1/9/2019 due to a decline in the volatility index and total return index.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to D+ from C- on 1/9/2019 due to a decline in the volatility index and total return index.
C
Hold
12/20/2018Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to C- from C on 12/20/2018 due to a significant decline in the volatility index and total return index.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to C- from C on 12/20/2018 due to a significant decline in the volatility index and total return index.
C
Hold
8/14/2018Downgrade
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to C from B- on 8/14/2018 due to a substantial decline in the valuation index, growth index and efficiency index. Net income declined 525.82% from $51.54M to -$219.45M, operating cash flow declined 464.72% from $27.03M to -$98.58M, and earnings per share declined from $0.2727 to -$0.1503.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to C from B- on 8/14/2018 due to a substantial decline in the valuation index, growth index and efficiency index. Net income declined 525.82% from $51.54M to -$219.45M, operating cash flow declined 464.72% from $27.03M to -$98.58M, and earnings per share declined from $0.2727 to -$0.1503.
B
Buy
8/7/2018Upgraded
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to B- from C+ on 8/7/2018 due to a large increase in the total return index.
Amneal Pharmaceuticals, Inc. (AMRX) was upgraded to B- from C+ on 8/7/2018 due to a large increase in the total return index.
C
Hold
7/31/2018None
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to C+ from U on 07/31/2018.
Amneal Pharmaceuticals, Inc. (AMRX) was downgraded to C+ from U on 07/31/2018.
NASDAQ
04/04/2025 12:57PM Eastern
Quotes delayed
